Real-World Data on Empagliflozin and Dapagliflozin Use in Patients with HEART Failure: The RED–HEART Study

Kocabas, U; Ergin, I; Yavuz, V; Altın, C; Kaplan, M; Yılmaz Öztekin, GM; Doğduş, M; Murat, S; Murat, B; Kıvrak, T; Karabulut, D; Kaya, E; Özdemir, İH; Yıldız, C; Salkın, FÖ; Özçalık, E; Polatkan, ŞG; Çakan, F; Şen, T; Karabulut, U; Çakal, S; Oflar, E; Sinan, ÜY; Yenerçağ, M; Türk, UÖ

doi:10.1002/ehf2.15049

Heart failure & cardiomyopathies

Real-World Data on Empagliflozin and Dapagliflozin Use in Patients with HEART Failure: The RED–HEART Study

ESC Heart FailPublished 28 Sep 2024Cross-sectional study

Read the original article ↗PubMed

Cite

Authors' conclusion

The RED-HEART study provided comprehensive real-world data about implementing SGLT2is in patients with HF.

Study context

Population: Outpatients with heart failure (HF) regardless of EF, 19 cardiology centres, August–December 2023
Participants: 1,923 outpatients

Exposure: HF with preserved ejection fraction vs HF with mildly reduced ejection fraction vs HF with reduced ejection fraction
Outcome: Use of SGLT2 inhibitors and clinical factors associated with their use

Methodological detailsmulticentre, observational, 19 cardiology centres

Multicentre
Observational
19 cardiology centres

Main finding

As reported in the abstract

SGLT2 inhibitor use

HFpEF42.0%

HF with mildly reduced EF47.9%

HFrEF50.6%

Overall SGLT2 inhibitor use: 925 (48.1%)
Difference across EF categories: P = 0.012

Observational data: associations, not effects.

Further findings

SGLT2i use by comorbidity

HF and diabetes76.6%

HF and chronic kidney disease19.8%

Without diabetes and chronic kidney disease26.8%

Factors independently associated with SGLT2i use (multivariable)

	← Lower odds ←→ Higher odds →	OR (95% CI)	P value
Higher education levelIndependently associated	0.050.21520	1.80 (1.06–3.05)	P = 0.027
Higher household incomeIndependently associated	0.050.21520	3.46 (1.27–9.42)	P = 0.015
NYHA class IVIndependently associated	0.050.21520	2.72 (1.16–6.35)	P = 0.021
DiabetesIndependently associated	0.050.21520	9.42 (6.72–13.20)	P < 0.001
ARNi useIndependently associated	0.050.21520	4.09 (2.39–7.01)	P < 0.001
MRA useIndependently associated	0.050.21520	2.02 (1.49–2.75)	P < 0.001
Loop diuretic useIndependently associated	0.050.21520	1.62 (1.18–2.22)	P = 0.003
Thiazide diuretic useIndependently associated	0.050.21520	1.72 (1.30–2.29)	P < 0.001
	0.050.21520Odds ratio (log scale)

Factors independently associated with non-use of SGLT2is

	← Lower ←→ Higher →	OR (95% CI)	P value
AF	0.20.5125	0.63 (0.45–0.88)	P = 0.008
Chronic kidney disease	0.20.5125	0.53 (0.37–0.76)	P = 0.001
Dihydropyridine calcium channel blocker use	0.20.5125	0.68 (0.48–0.98)	P = 0.042
Statin use	0.20.5125	0.67 (0.49–0.91)	P = 0.010
	0.20.5125Odds ratio (log scale)

SGLT2i use by comorbidity: P < 0.001

Reference

Authors: Kocabas U, Ergin I, Yavuz V, Altın C, Kaplan M, Yılmaz Öztekin GM, et al.
All 25 authors
Kocabas U, Ergin I, Yavuz V, Altın C, Kaplan M, Yılmaz Öztekin GM, Doğduş M, Murat S, Murat B, Kıvrak T, Karabulut D, Kaya E, Özdemir İH, Yıldız C, Salkın FÖ, Özçalık E, Polatkan ŞG, Çakan F, Şen T, Karabulut U, Çakal S, Oflar E, Sinan ÜY, Yenerçağ M, Türk UÖ
Journal: ESC Heart Failure
Published: 28 Sep 2024
DOI: 10.1002/ehf2.15049
PubMed: 39340234

Topic: Heart failure & cardiomyopathies

Exposure definitions

HF with preserved ejection fraction: 22.1% of the study population
HF with mildly reduced ejection fraction: 21.5% of the study population
HF with reduced ejection fraction: 56.4% of the study population

Key notes

HFpEF 22.1%, HF with mildly reduced EF 21.5%, HFrEF 56.4% of population

Original publication

Real-World Data on Empagliflozin and Dapagliflozin Use in Patients with HEART Failure: The RED–HEART Study. ESC Heart Fail. Published 28 September 2024. doi:10.1002/ehf2.15049

Read the original article ↗

Composed by AI from the published abstract and checked against it. How Briefs are made →